产妇血清表面抗原定量与乳汁中乙肝病毒载量的相关性分析

目的 探讨携带乙型肝炎病毒(HBV)的产妇血清表面抗原(HBsAg)含量与乳汁中HBV-DNA含量的相关性,并指导母乳喂养.方法 对140例产妇采用荧光定量PCR法测定乳汁中HBV-DNA和化学发光法测定表面抗原含量,并进行相关性分析.结果 A组乳汁HBV-DNA阳性组表面抗原含量为(58 183.2±39 147.8) IU/ml,B组HBV-DNA阴性组表面抗原含量为(1848.8±2458.3) IU/ml.A组血清中表面抗原含量比B组高,差异有统计学意义(P＜0.01),乳汁中HBV-DNA含量与血清中表面抗原含量呈正相关(r=0.799,P＜0.01).结论 慢性HBV感染孕产妇血清中乙肝表面抗原的定量的测定及检测其乳汁中HBV-DNA含量,对阻断母婴传播和预防家庭内水平传播及对HBV感染孕产妇的诊治和疗效评估有着重要意义,特别是为HBV感染产妇选择是否母乳喂养提供了指导依据.     

Prevention of perinatal hepatitis B transmission in Haimen City,China: Results of a community public health initiative

In regions where hepatitis B virus (HBV) is endemic, perinatal transmission is common. Infected newborns have a 90% chance of developing chronic HBV infection, and 1 in 4 will die prematurely from HBV-related liver disease. In 2010, the Hepatitis B Foundation and the Haimen City CDC launched the Gateway to Care campaign in Haimen City, China to improve awareness, prevention, and control of HBV infection citywide. The campaign included efforts to prevent perinatal HBV transmission by screening all pregnant women for hepatitis B surface antigen (HBsAg), following those who tested positive, and administering immunoprophylaxis to their newborns at birth. Of 5407 pregnant women screened, 185 were confirmed HBsAg-positive and followed until delivery. At age one, 175 babies were available for follow up testing. Of those, 137 tested negative for HBsAg and positive for antibodies to HBsAg, indicating protection. An additional 34 HBsAg-negative babies also tested negative for antibodies to HBsAg or had indeterminate test results, were considered to have had inadequate immune responses to the vaccine, and were given a booster dose. A higher prevalence of nonresponse to HBV vaccine was observed among babies born to hepatitis B e antigen (HBeAg)-positive mothers and mothers with high HBV DNA titers. The remaining 4 babies tested positive for HBsAg and negative for antibodies, indicative of active HBV infection. The mothers of all 4 had viral loads ≥8 × 10⁶ copies/ml in the third trimester. Although inadequate response or nonresponse to HBV vaccine was more common among babies born to HBeAg-positive and/or high viral load mothers, these risk factors did not completely predict nonresponsiveness. All babies born to HBV-infected mothers should be tested upon completion of the vaccine series to ascertain adequate protection. Some babies of HBeAg-positive mothers with high viral load may still become HBV infected despite timely immunoprophylaxis with HBV vaccine and HBIG.     

抗HBsAg Fab片段和α-干扰素融合蛋白的克隆及表达

目的 为深入研究乙型肝炎的生物导向治疗，构建以人抗乙型肝炎表面抗原（ＨＢｓＡｇ）抗本Ｆａｂ片段国导向作用，αＡ－干扰素（ＩＦＮ－αＡ）为治疗作用的融合蛋白Ｆａｂ／ＩＦＮ－αＡ原核表达载体ｐＨＳ／ＩＦＮ－αＡ。方法 用ＰＣＲ体外扩增目的基因ＩＦＮ－αＡ，并在其ＤＮＡ两端引入酶切点及５′端人工合成的Ｌｉｎｋｅｒ，重组人抗ＨＢｓＡｇ缺本Ｆａｂ片段功体ｐＨＳ相应酶切位点，酶切位点，酶切和ＤＮＡ测序鉴定筛选     

2006年新疆库尔勒市1 311名中学生HBsAg检测分析

为了解新疆库尔勒市在校学生乙型肝炎病毒携带情况,更好地采取预防为主和防治并举的措施,于2006年4月对库尔勒市某中学的在校学生进行了HBsAg检测。1对象与方法2006年4月对库尔勒市某中学在校中学生进行了HBsAg检测,共计1 311人,其中男生612人,女生699人。采用酶联免疫法检测Hb     

单纯检测HBsAg筛选献血者的危险性

HBV感染导致乙型病毒性肝炎(以下简称乙肝)已众所周知,而乙肝的诊断一直主要依靠检测血清中的特异性抗原和抗体.     

用乙肝诊断试剂盒对新疆野生啮齿动物进行血清学调查

目的调查新疆野生啮齿动物的血清中乙型肝炎病毒表面抗原的存在状态.方法应用乙肝表面抗原诊断试剂盒和乙肝表面抗体诊断试剂盒,对野生啮齿动物进行了血清学调查.结果灰旱獭(Marmota baibacina)的阳性率为17.8%(24/135)、长尾黄鼠(Citellus undulatus)阳性率为17.4%(12/69)和赤颊黄鼠(Citellus erythrogenys)阳性为(8/15).结论血清学调查表明,野生啮齿动物血清中存在乙型肝炎病毒表面抗原.     

慢性HBsAg携带者及非活动性HBV感染状态的病理学研究

目的观察临床诊断为慢性HBsAg携带者及病理诊断为非活动性HBV感染状态患者的临床病理特点。方法总结慢性HBsAg携带者41例、非活动性HBV感染状态患者65例的临床资料,通过HE、组织化学及免疫组织化学染色观察其肝穿刺组织切片的病理变化。结果慢性HBsAg携带者41例无明显异常的症状体征,各项肝功能检查基本正常;但肝穿组织病理检查仅有10例无明显病变,30例为轻度慢性乙型肝炎,1例为静止性肝硬化。非活动性HBV感染状态患者65例中,少数患者有较轻的肝功能异常改变;病理检查无明显炎症和纤维化。结论慢性HBsAg携带者主要是一组以轻度慢性乙型肝炎表现为主的患者,非活动性HBV感染状态患者也仅有轻度的肝功能异常;慢性HBsAg携带者及非活动性HBV感染状态是临床医师和病理医师对同一类病变的不同诊断用词,对其诊断应结合临床和病理资料综合判断。     

Occult infection with HBV intergenotypic A2/G recombinant following acute hepatitis B caused by an HBV/A2 isolate

Viral and host factors leading to occult hepatitis B virus (HBV) infection (OBI) are not fully understood. Whether HBV genotype may influence the occurrence and course of OBIs is unknown. Here, we describe the case of a patient infected with HBV genotype A2 who developed symptomatic acute hepatitis and did not seroconvert after loss of HBsAg and HBeAg. The acute phase of hepatitis B was followed by a period of more than 2 years during which the DNA of an intergenotypic HBV/A2/G recombinant was intermittently detected in serum.     

定量检测710例肝病患者HBsAg和H BeAg临床意义

目的：了解乙型肝炎与肝硬化患者表面抗原（HBsAg）与e抗原（HBeAg）定量变化规律,探讨分层次联合抗病毒治疗并争取满意效果的可行性。方法采用荧光磁微粒酶免法检测710例 HBV 相关肝病患者 HBsAg 和HBeAg,用SPSS19．0软件包进行统计学处理。结果 HBsAg＜0．2 IU/mL 61例,占8．5％;HBsAg＞0．2 IU/mL～＜100 IU/mL 为低水平 HBsAg组,55例,占7．7％;HBsAg ＞100 IU/mL～＜1000 IU/mL 为中等水平 HBsAg 组,142例,占20％;HBsAg 1000～5000 IU/mL为高水平 HBsAg 组,211例,占29．7％;HBsAg＞5000 IU/mL 为超高水平HBsAg组,241例,占33．9％;各型肝炎随年龄增大,HBsAg 定量值逐步下降,转阴高峰集中在46岁左右;HBeAg 阴性组（＜1．0 CI）453例,占63．8％;低水平 HBeAg阳性组（＞1．0 CI～＜10 CI）96例,占13．5％;中等量水平 HBeAg 阳性组（＞10 CI～＜100 CI）55例,占7．7％;高水平 HBeAg 阳性组（＞100 CI～＜500 CI）23例,占3．2％;超高水平HBeAg阳性组（＞500 CI）83例,占11．6％;从慢性 HBV携带者,慢性乙型肝炎,代偿期肝硬化到失代偿期肝硬化,年龄逐步增大,HBsAg和 HBeAg定量秩均值逐步下降,卡方检验有显著性差异。结论 HBsAg 和 HBeAg 定量随年龄增加与病情发展逐步下降,根据 HBsAg,HBeAg 和 HBV DNA定量进行分层次联合抗病毒治疗可争取较满意效果。